1-6 of 6
chimeric antigen receptor t-cell therapy
Close
Sort by
Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.
https://doi.org/10.1182/hematology.2019000068
Published: 2019
Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.
https://doi.org/10.1182/hematology.2019000370
Published: 2019
Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.
https://doi.org/10.1182/asheducation-2018.1.9
Published: 2018
Journal Articles

Are CAR T cells better than antibody or HCT therapy in B-ALL?

Michael A. Pulsipher
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 16–24.
https://doi.org/10.1182/asheducation-2018.1.16
Published: 2018
Journal Articles

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia

Noelle V. Frey, David L. Porter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 567–572.
https://doi.org/10.1182/asheducation-2016.1.567
Published: 2016
Journal Articles

Chimeric antigen receptor T-cell therapy for ALL

Shannon L. Maude, Elizabeth J. Shpall, Stephan A. Grupp
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 559–564.
https://doi.org/10.1182/asheducation-2014.1.559
Published: 2014